Terms: = Prostate cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
57 results:
1. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
2. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract] [Full Text] [Related]
3. Tumor-associated macrophages and pd-l1 in prostate cancer: a possible key to unlocking immunotherapy efficacy.
Wang J; Wu W; Yuan T; Wang L; Zang L; Liu Q; Wang L; Huo X; Huo B; Tang Y; Wang H; Zhao Z
Aging (Albany NY); 2024 Jan; 16(1):445-465. PubMed ID: 38189834
[TBL] [Abstract] [Full Text] [Related]
4. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive analysis of integrin αvβ3/α6β1 in prognosis and immune escape of prostate cancer.
Liu Y; He JX; Ji B; Wang JF; Zhang L; Pang ZQ; Wang JS; Ding BC; Ren MH
Aging (Albany NY); 2023 Oct; 15(20):11369-11388. PubMed ID: 37862114
[TBL] [Abstract] [Full Text] [Related]
6. A Crosstalk Between Castration-Resistant prostate cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-pd-l1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract] [Full Text] [Related]
7. N
Wang Y; Jin P; Wang X
Apoptosis; 2024 Feb; 29(1-2):142-153. PubMed ID: 37698736
[TBL] [Abstract] [Full Text] [Related]
8. A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer.
Chen JY; Huang XY; Lin F; You Q; Xue YT; Lin B; Zheng QS; Wei Y; Xue XY; Li XD; Chen DN; Xu N
Genomics; 2023 Sep; 115(5):110691. PubMed ID: 37516327
[TBL] [Abstract] [Full Text] [Related]
9. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract] [Full Text] [Related]
10. A glycosylation signature for predicting the progression and immunotherapeutic response of prostate cancer.
Sun K; Feng Z; Fan C; Min X; Zhang P; Xia L
J Gene Med; 2023 Jun; 25(6):e3489. PubMed ID: 36814131
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract] [Full Text] [Related]
12. The cGAS-STING pathway-related gene signature can predict patient prognosis and immunotherapy responses in prostate adenocarcinoma.
Zhuo X; Dai H; Yu S
Medicine (Baltimore); 2022 Dec; 101(50):e31290. PubMed ID: 36550819
[TBL] [Abstract] [Full Text] [Related]
13. Intratumoral immune heterogeneity of prostate cancer characterized by typing and hub genes.
Han J; Zhou Y; Zhang C; Feng J; Wang J; Guo K; Chen W; Li Y
J Cell Mol Med; 2023 Jan; 27(1):101-112. PubMed ID: 36524848
[TBL] [Abstract] [Full Text] [Related]
14. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein b7-h3, and with poor prognosis in prostate cancer.
Nunes-Xavier CE; Emaldi M; Guldvik IJ; Ramberg H; Taskén KA; Mælandsmo GM; Fodstad Ø; Llarena R; Pulido R; López JI
Pathol Res Pract; 2023 Jan; 241():154243. PubMed ID: 36481650
[TBL] [Abstract] [Full Text] [Related]
15. The Oncogenic and Immunological Roles of Apoptosis Antagonistic Transcription Factors in Human Tumors: A Pan-cancer Analysis.
Lu F; Wu J; Zou H; Yang X; Wu Y; Xu J
Oxid Med Cell Longev; 2022; 2022():3355365. PubMed ID: 36275893
[TBL] [Abstract] [Full Text] [Related]
16. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract] [Full Text] [Related]
17. Immune Evasion and Drug Resistance Mediated by USP22 in cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract] [Full Text] [Related]
18. The association between PI3K, JAK/STAT pathways with the PDL-1 expression in prostate cancer.
Kazan O; Kir G; Culpan M; Cecikoglu GE; Atis G; Yildirim A
Andrologia; 2022 Nov; 54(10):e14541. PubMed ID: 35880672
[TBL] [Abstract] [Full Text] [Related]
19. Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway.
Zhang J; Li S; Zhang J; Zhang W; Jiang J; Wu H; Wu E; Feng Y; Yang L; Li Z
Cancer Lett; 2022 Oct; 545():215829. PubMed ID: 35868534
[TBL] [Abstract] [Full Text] [Related]
20. Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.
Trigos AS; Pasam A; Banks P; Wallace R; Guo C; Keam S; Thorne H; ; Mitchell C; Lade S; Clouston D; Hakansson A; Liu Y; Blyth B; Murphy D; Lawrentschuk N; Bolton D; Moon D; Darcy P; Haupt Y; Williams SG; Castro E; Olmos D; Goode D; Neeson P; Sandhu S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764368
[TBL] [Abstract] [Full Text] [Related]
[Next]
